Ares Management Corporation announced that its Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI. This financing is specifically intended to support Tempus’ previously announced acquisition of Ambry Genetics, which closed on February 3, 2025.
Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have now provided Tempus with a total debt package of approximately $560 million. This substantial financing underscores Ares’ ability to provide flexible capital at scale.
The investment supports Tempus’s growth strategy and the complementary acquisition of Ambry, which expands Tempus’s AI-enabled solutions in precision medicine. This financial backing is crucial for Tempus to continue its efforts in advancing medicine across oncology, cardiology, pathology, and radiology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.